The landscape of biotechnology in Spain is set to undergo a significant transformation with the recent investment by the SICC Innvierte fund of CDTI Innovación in InceptionBio. This fund is dedicated to promoting the establishment of biotechnology companies and advancing early-stage technology transfer projects.
This investment underscores CDTI Innovación’s commitment to accelerating technology transfer and fostering the creation of new technology-based companies that possess high growth potential. The initiative aims to bolster the competitiveness of the Spanish R&D system, positioning it as a leader in the biotech sector.
INCEPTIONBIO INNVIERTE, FCRE (InceptionBio) is a newly launched fund by Ysios Capital, a prominent European venture capital manager specializing in life sciences. The fund is designed to support the creation of biotech companies and the development of early-stage projects, focusing on innovative solutions that address pressing medical needs.
The first closing of the fund occurred in March, with CDTI Innovación participating through Innvierte, committing €70.56 million. This substantial backing highlights the confidence in InceptionBio’s mission and the potential for growth within the Spanish biotech ecosystem.
InceptionBio aims to identify, develop, and build new companies grounded in excellent scientific research, with a particular emphasis on Spain. The fund will primarily invest in technology transfer projects and early-stage companies, working closely with universities, research centers, and entrepreneurs to transform scientific discoveries into impactful therapies.
The strategy of InceptionBio is multifaceted. It combines the creation of new companies from scientific assets developed in academic institutions with the identification and attraction of international assets that can be developed in Spain. This approach not only strengthens the national ecosystem but also positions Spain as a reference hub for biotechnology.
Currently, InceptionBio has a pipeline of investment opportunities that are in an advanced stage of analysis. As part of its deployment plan, the fund aims to establish at least three new biotech companies by 2026, showcasing its proactive approach to fostering innovation.
The collaboration with CDTI Innovación through Innvierte reinforces public-private partnerships in a critical area for the development of the Spanish biotech ecosystem. This partnership is expected to accelerate technology transfer, encourage the creation of high-growth technology-based companies, and enhance the competitiveness of the Spanish R&D system.
Ysios Capital
Ysios Capital is a leading Spanish venture capital firm that focuses on funding highly innovative life sciences companies. These companies are dedicated to developing treatments for diseases that currently have significant unmet medical needs. With offices in San Sebastián and Barcelona, Ysios Capital boasts a diverse team of professionals committed to transforming capital into medical breakthroughs, generating both financial returns and positive social impact.
Founded in 2008, the firm manages over €450 million in assets across three funds. It also serves as an investment advisor to the listed Telescope Biotech Fund, managed by Andbank Wealth Management. Throughout its history, Ysios Capital has invested in more than 40 biotech companies, achieving 6 NASDAQ exits and 11 M&A divestments, solidifying its position as one of Europe’s leading sector investors.
With InceptionBio, Ysios Capital expands its capacity to support biomedical innovation across the entire value chain, from very early stages to more advanced developments. The team brings extensive experience in innovation, entrepreneurship, and the development of life sciences companies, having participated in the creation, management, and growth of multiple biotech firms over the past two decades.
Innvierte
Innvierte is an initiative designed to promote business innovation by supporting venture capital investments in technology-based or innovative companies. This program is implemented through the closed-ended collective investment scheme Innvierte Economía Sostenible SICC S.M.E., which is self-managed and supervised by the Spanish National Securities Market Commission (CNMV), with CDTI Innovation as its sole shareholder.
To date, CDTI Innovación has committed €3,478.5 million through Innvierte across 61 investment vehicles. Additionally, through its co-investment line, it has directly committed €866.1 million in 197 companies. This substantial investment reflects the initiative’s dedication to fostering innovation and growth within the Spanish business landscape.
Innvierte is part of the Spanish Strategy for Science, Technology, and Innovation 2021–2027, which was approved by the Council of Ministers in September 2020. This strategy outlines the objectives, reforms, and measures necessary to drive growth and impact across the entire R&D&I ecosystem, serving as a cornerstone of the Government’s innovation policy for the coming years.
CDTI Innovación
The Centre for the Development of Industrial Technology and Innovation (CDTI E.P.E.) is the innovation agency of the Spanish Ministry of Science, Innovation, and Universities. Its primary responsibility is to promote technological innovation within the business sector. CDTI Innovación aims to ensure that the Spanish business ecosystem effectively generates and transforms scientific and technical knowledge into sustainable, inclusive, and globally competitive growth. In 2025, under its Strategic Plan 2024–2027, CDTI is set to provide over €2 billion in support to Spanish companies and startups.
More info:
Web: www.cdti.es
LinkedIn: https://www.linkedin.com/company/cdti/
X: https://x.com/CDTI_innovacion
YouTube: https://www.youtube.com/user/CDTIoficial
Web: www.innvierte.es
Ysios Capital:
Web: www.ysioscapital.com
LinkedIn: https://www.linkedin.com/company/ysios-capital
X: https://x.com/YsiosCapital
